MIDOL Drug Patent Profile
✉ Email this page to a colleague
When do Midol patents expire, and what generic alternatives are available?
Midol is a drug marketed by Bayer and Bionpharma and is included in five NDAs.
The generic ingredient in MIDOL is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and thirty-four suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Midol
A generic version of MIDOL was approved as ibuprofen by STRIDES PHARMA on September 24th, 1986.
Summary for MIDOL
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 207 |
Patent Applications: | 5,097 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MIDOL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for MIDOL
US Patents and Regulatory Information for MIDOL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer | MIDOL | ibuprofen | CAPSULE;ORAL | 070626-001 | Sep 2, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bayer | MIDOL | ibuprofen | TABLET;ORAL | 071001-001 | Sep 2, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bayer | MIDOL | ibuprofen | CAPSULE;ORAL | 071002-001 | Sep 2, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MIDOL
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Recordati Rare Diseases | Pedea | ibuprofen | EMEA/H/C/000549 Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. |
Authorised | no | no | no | 2004-07-28 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |